Cannabinoid receptor ligands as potential anticancer agents - High hopes for new therapies?

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 7, 2009, Pages 839-853

  Oesch, Susanne ^a   Gertsch, Jürg ^b,c  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anticancer agent; Cancer; Cannabinoids; Chemoprevention; Endocannabinoid system

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 AG; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 AG; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3,3' DIINDOLMETHANE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AJULEMIC ACID; ANANDAMIDE; ANTINEOPLASTIC AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CAPASZEPINE; CERAMIDE; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR 55; METHANANDAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P8; RIMONABANT; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR; LIGAND; TETRAHYDROCANNABINOL;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL CYCLE ARREST; CELL PROLIFERATION; DRUG MECHANISM; HUMAN; IN VITRO STUDY; NONHUMAN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG POTENTIATION; DRUG SCREENING; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CANNABINOIDS; DRUG EVALUATION, PRECLINICAL; ENDOCANNABINOIDS; HUMANS; LIGANDS; NEOPLASMS; RECEPTORS, CANNABINOID; TETRAHYDROCANNABINOL;

EID: 69149097969     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.07.0002     Document Type: Review

References (178)

1. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 2006; 46: 101-122.
2. Matsuda LA et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
3. Munro S et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
4. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 152: 567-575.
5. Ryberg E et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-1101.
6. Overton et al. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol 2008; 153: 76-81.
7. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 2006; 8: E298-E306.
8. Kreitzer FR, Stella N. The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther 2009; 122: 83-96.
9. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008; 160: 1-24.
10. Hanus LO. Discovery and isolation of anandamide and other endocannabinoids. Chem Biodivers 2007; 4: 1828-1841.
11. Ross RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003; 140: 790-801.
12. Lenman A, Fowler CJ. Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system. Br J Pharmacol 2007; 151: 1343-1351.
13. Racz I et al. Anandamide effects on 5-HT(3) receptors in vivo. Eur J Pharmacol 2008; 596: 98-101.
14. Ross RA. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 2009; 30: 156-163.
15. Bab I et al. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 2008; 20(Suppl 1): 69-74.
16. Maccarrone M, Finazzi-Agro A. The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ 2003; 10: 946-955.
17. Patinkin D et al. Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation. Eur J Pharmacol 2008; 595: 1-6.
18. Mechoulam R, Gaoni Y, Hashish IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 1965; 21: 1223-1229.
19. Devane WA et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-613.
20. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008; 7: 438-455.
21. Lange JH, Kruse CG. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives. Chem Rec 2008; 8: 156-168.
22. Machado Rocha FC et al. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 2008; 17: 431-443.
23. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-411.
24. Ashton JC. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs 2007; 8: 373-384.
25. Parfienuk A et al. Role of cannabinoids in chronic liver disease. World J Gastroenterol 2008; 14: 6109-6114.
26. Wolf SA et al. CNS immune surveillance and neuroinflammation: endocannabinoids keep control. Curr Pharm Des 2008; 14: 2266-2278.
27. Di Marzo V, Izzo AA. Endocannabinoid overactivity and intestinal inflammation. Gut 2006; 55: 1371-1376.
28. Karsak M et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007; 316: 1494-1497.
29. Lunn CA et al. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol 2008; 153: 226-239.
30. Buckley NE. The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 2008; 153: 309-318.
31. Idris AI et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005; 11: 774-779.
32. Karsak M et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 2005; 14: 3389-3396.
33. Ofek O et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 2006; 103: 696-701.
34. Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol 2008; 153: 182-188.
35. Izzo AA. The cannabinoid CB(2) receptor: a good friend in the gut. Neurogastroenterol Motil 2007; 19: 704-708.
36. Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 2007; 5: 73-80.
37. Steffens S et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434: 782-786.
38. Mach F, Steffens S. The role of the endocannabinoid system in atherosclerosis. J Neuroendocrinol 2008; 20(Suppl 1): 53-57.
39. Jhaveri MD et al. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007; 152: 624-632.
40. Bifulco M, Di Marzo V. [The endocannabinoid system as a target for the development of new drugs for cancer therapy]. Recenti Prog Med 2003; 94: 194-198.
41. Bifulco M et al. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 2006; 148: 123-135.
42. Flygare J, Sander B. The endocannabinoid system in cancer-potential therapeutic target? Semin Cancer Biol 2008; 18: 176-189.
43. Sarfaraz S et al. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008; 68: 339-342.
44. Munson AE et al. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975; 55: 597-602.
45. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4: 682-690.
46. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007; 7: 79-94.
47. Velasco G et al. Cannabinoids and ceramide: two lipids acting hand-by-hand. Life Sci 2005; 77: 1723-1731.
48. Sanchez C et al. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998; 436: 6-10.
49. Sanchez C et al. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol- induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 1998; 54: 834-843.
50. Carracedo A et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 2000; 9: 301-312.
51. Gomez del Pulgar T et al. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 2002; 363: 183-188.
52. Blazquez C et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 2008; 68: 1945-1952.
53. Blazquez C et al. Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology 2008; 54: 235-243.
54. Cianchi F et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin Cancer Res 2008; 14: 7691-7700.
55. Carracedo A et al. Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. Biochem J 2004; 380: 435-440.
56. Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 2005; 4: 677-684.
57. Parcellier A et al. PKB and the mitochondria: AKTing on apoptosis. Cell Signal 2008; 20: 21-30.
58. Andrews S et al. PI3K class IB pathway. Sci STKE 2007: cm2.
59. Stephens L et al. A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell 1994; 77: 83-93.
60. Gomez Del Pulgar T et al. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 2002; 277: 36527-36533.
61. Gomez del Pulgar T et al. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 2000; 347: 369-373.
62. Ozaita A et al. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 2007; 102: 1105-1114.
63. Fang J et al. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 2007; 19: 2487-2497.
64. Hart S et al. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004; 64: 1943-1950.
65. Greenhough A et al. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer 2007; 121: 2172-2180.
66. Sarfaraz S et al. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 2006; 281: 39480-39491.
67. Blazquez C et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006; 20: 2633-2635.
68. Galve-Roperh I et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extra-cellular signal-regulated kinase activation. Nat Med 2000; 6: 313-319.
69. Melck D et al. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 1999; 463: 235-240.
70. Preet A et al. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 2008; 27: 339-346.
71. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 2008; 65: 3525-3544.
72. Gertsch J et al. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci USA 2008; 105: 9099-9104.
73. Encinar JA et al. Human p8 is a HMG-I/Y-like protein with DNA binding activity enhanced by phosphorylation. J Biol Chem 2001; 276: 2742-2751.
74. Carracedo A et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006; 66: 6748-6755.
75. Caffarel MM et al. JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene 2008; 27: 5033-5044.
76. Widmer M et al. High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells. J Neurosci Res 2008; 86: 3212-3220.
77. Jia W et al. Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res 2006; 4: 549-562.
78. Galanti G et al. Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol 2008; 47: 1062-1070.
79. Portella G et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 2003; 17: 1771-1773.
80. Laezza C et al. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett 2006; 580: 6076-6082.
81. Caffarel MM et al. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 2006; 66: 6615-6621.
82. Ellert-Miklaszewska A et al. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal 2005; 17: 25-37.
83. Bifulco M et al. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review). Oncol Rep 2007; 17: 813-816.
84. Blazquez C et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003; 17: 529-531.
85. Casanova ML et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003; 111: 43-50.
86. Nyberg P et al. Tumor microenvironment and angiogenesis. Front Biosci 2008; 13: 6537-6553.
87. Pisanti S et al. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol 2007; 211: 495-503.
88. De Filippis D et al. Cannabinoids reduce granulomaassociated angiogenesis in rats by controlling transcription and expression of mast cell protease-5. Br J Pharmacol 2008; 154: 1672-1679.
89. 2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 2008; 294: H1145-H1155.
90. Miller AM, Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 2008; 153: 299-308.
91. Molina-Holgado F et al. CB2 cannabinoid receptors promote mouse neural stem cell proliferation. Eur J Neurosci 2007; 25: 629-634.
92. Valk PJ et al. Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincide with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2. J Virol 1999; 73: 3595-3602.
93. Joosten M et al. Leukemic predisposition of pSca-1/Cb2 transgenic mice. Exp Hematol 2002; 30: 142-149.
94. Jorda MA et al. Identification, characterization, and function of a novel oncogene: the peripheral cannabinoid receptor Cb2. Ann NY Acad Sci 2003; 996: 10-16.
95. Gertsch J. Antiinflammatory cannabinoids in diet - towards a better understanding of CB2 receptor action? Commun Integr Biol 2008; 1: 26-28.
96. Smith SR et al. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 2000; 293: 136-150.
97. Ashton JC et al. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr Med Chem 2008; 15: 1428-1443.
98. Gustafsson K et al. Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol Pharmacol 2006; 70: 1612-1620.
99. McAllister SD et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol 2005; 74: 31-40.
100. Massi P et al. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci 2006; 63: 2057-2066.
101. Contassot E et al. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol Oncol 2004; 93: 182-188.
102. Goncharov I et al. Delta9-tetrahydrocannabinol increases C6 glioma cell death produced by oxidative stress. Neuroscience 2005; 134: 567-574.
103. Massi P et al. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 2004; 308: 838-845.
104. Hinz B et al. Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol Pharmacol 2004; 66: 1643-1651.
105. Fowler CJ et al. Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. Biochem Pharmacol 2003; 66: 757-767.
106. Jacobsson SO et al. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 2001; 299: 951-959.
107. Recht LD et al. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem Pharmacol 2001; 62: 755-763.
108. Sanchez C et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001; 61: 5784-5789.
109. Krishnamurthy M et al. Exploring the substituent effects on a novel series of C1′-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem 2008; 16: 6489-6500.
110. Cabral GA et al. Interaction of delta-9-tetrahydrocannabinol with rat B103 neuroblastoma cells. Arch Toxicol 1987; 60: 438-449.
111. End DW et al. A comparative study of the disposition of (-)-delta 9-tetrahydrocannabinol in neuroblastoma and glioma cells in tissue culture: relation cellular impairment. Mol Pharmacol 1977; 13: 864-871.
112. McKallip RJ et al. Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol 2006; 70: 897-908.
113. Herrera B et al. p38 MAPK is involved in CB2 receptor induced apoptosis of human leukaemia cells. FEBS Lett 2005; 579: 5084-5088.
114. Lombard C et al. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res 2005; 29: 915-922.
115. McKallip RJ et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002; 100: 627-634.
116. Dvilansky A et al. Effects of ethanol, CBD and delta THC on proliferation of K-562 cells. Int J Tissue React 1984; 6: 409-412.
117. Tucker AN, Friedman MA. Effects of cannabinoids on L1210 murine leukemia. 1. Inhibition of DNA synthesis. Res Commun Chem Pathol Pharmacol 1977; 17: 703-714.
118. Carchman RA et al. The inhibition of DNA synthesis by cannabinoids. Cancer Res 1976; 36: 95-100.
119. Flygare J et al. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett 2005; 579: 6885-6889.
120. Gustafsson SB et al. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol 2008; 63: 691-701.
121. Friedmann MA. In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas. Cancer Biochem Biophys 1977; 2: 51-54.
122. White AC et al. Effects of delta9-tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J Natl Cancer Inst 1976; 56: 655-658.
123. Patsos HA et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 2005; 54: 1741-1750.
124. Ligresti A et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003; 125: 677-687.
125. Fogli S et al. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett 2006; 580: 1733-1739.
126. Sarnataro D et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol 2006; 70: 1298-1306.
127. De Petrocellis L et al. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol 2002; 16: 297-302.
128. Di Marzo V et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 2001; 358: 249-255.
129. Melck D et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000; 141: 118-126.
130. Bisogno T et al. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells-implications for cell proliferation and differentiation. Eur J Biochem 1998; 254: 634-642.
131. De Petrocellis L et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 1998; 95: 8375-8380.
132. Sarfaraz S et al. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 2005; 65: 1635-1641.
133. Mimeault M et al. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 2003; 56: 1-2.
134. Sarker KP et al. ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. J Neurochem 2003; 85: 50-51.
135. Ruiz L et al. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 1999; 458: 400-404.
136. Lee CY et al. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol 2008; 8: 732-740.
137. De Morrow S et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem 2007; 282: 13098-13113.
138. Giuliano M et al. Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma. Biochimie 2009; 91: 457-465.
139. Shi Y et al. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene Ther 2008; 15: 101-107.
140. Cozzolino R et al. A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis. Invest New Drugs 2009; Feb 3 (Epub ahead of print).
141. Yin H et al. Lipid G-protein-coupled receptor ligand identification using beta-arrestin pathhunter assay. J Biol Chem 2009; 284: 12328-12338.
142. Nguyen et al. The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing. Proc Natl Acad Sci USA 2008; 105: 19750-19755.
143. Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 2007; 152: 984-986.
144. Lauckner JE et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008; 105: 2699-2704.
145. Henstridge CM et al. The GPR55 ligand L-alpha- lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 2009; 23: 183-193.
146. Kondo E et al. NF-ATc induces apoptosis in Burkitt's lymphoma cells through signaling via the B cell antigen receptor. Eur J Immunol 2003; 33: 1-11.
147. Massi P et al. 5-Lipoxygenase and anadamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 2008; 104: 1091-1100.
148. Sarnataro D et al. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Lett 2005; 579: 6343-6349.
149. Starowicz K et al. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007; 114: 13-33.
150. Burstein S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci 2005; 77: 1674-1684.
151. Ramer R, Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expressionof tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 2008; 100: 59-69.
152. De Petrocellis L et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 2008; 325: 1007-1015.
153. Ambrosio Al et al. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. J Biol Chem 2007; 282: 18625-18633.
154. Sarfaraz S et al. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 2005; 65: 1635-1641.
155. Holland ML et al. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol 2008; 591: 128-131.
156. Holland ML et al. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol 2007; 152: 815-824.
157. Holland ML et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol 2006; 71: 1146-1154.
158. Nieri P et al. Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells. Br J Pharmacol 2006; 148: 682-687.
159. Zhu HJ et al. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther 2006; 317: 850-757.
160. Ligresti A et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006; 318: 1375-1387.
161. Zheng D et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 2008; 68: 3992-3998.
162. Aguado T et al. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem 2007; 282: 6854-6862.
163. Chung SC et al. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 2009; 45: 174-182.
164. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008; 4: 245-259.
165. Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 2007; 5: 1-9.
166. McKallip RJ et al. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 2005; 174: 3281-3289.
167. Mocellin S, Nitti D. TNF and cancer: the two sides of the coin. Front Biosci 2008; 13: 2774-2783.
168. Sethi G et al. TNF: a master switch for inflammation to cancer. Front Biosci 2008; 13: 5094-5107.
169. Wang D et al. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 2008; 68: 6468-6476.
170. Izzo AA et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med 2008; 86: 89-98.
171. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009; 156: 397-411.
172. Liu WM et al. Enhancing the in vitro cytotoxic activity of Delta-9-tetrahydrocannabinol in leukemic cells through combinatorial approach. Leuk Lymphoma 2008; 49: 1800-1809.
173. Desai AG et al. Medicinal plants and cancer chemoprevention. Curr Drug Metab 2008; 9: 581-591.
174. Parolaro D, Massi P. Cannabinoids as potential new therapy for the treatment of gliomas. Expert Rev Neurother 2008; 8: 37-49.
175. Sidney S et al. Marijuana use and cancer incidence (California, United States). Cancer Causes Control 1997; 8: 722-728.
176. Aldington S et al. Cannabis use and risk of lung cancer: a case-control study. Eur Respir J 2008; 31: 280-286.
177. Sewell RA et al. Doubts about the role of cannabis in causing lung cancer. Eur Respir J 2008; 32: 815-816.
178. Daling et al. Association of marijuana use and the incidence of testicular germ cell tumors. Cancer 2009; 115: 1215-1223.